Cipla filed its complaint under seal late Friday in the U.S. District Court for the District of Delaware, according to court papers filed concurrently. It also filed four exhibits under seal because they contain confidential information related to Cipla’s application with the U.S. Food and Drug Administration to sell its Ofev copycat. Two of the exhibits “contain Cipla’s regulatory strategy” related to that …